Drug Discovery & DDS– category –
-
Synthetic Small Molecule API Market to See Growth through 2035, Driven by Oncology Pipeline and Generic Demand, Report Says
IndexBox Global Overview This article provides an overview of a market research report published by IndexBox, which forecasts growth in the global synthetic small molecule API market, driven by increasing chronic disease prevalence, a ro... -
Contract Organizations’ Pivotal Role in Lentiviral Manufacturing Accelerates Gene Therapy Commercialization
MAI CDMO Global Overview This article highlights the essential role of Contract Development and Manufacturing Organizations (CDMOs) in lentiviral vector manufacturing, crucial for gene and cell therapies like CAR-T. Lentiviral vector pro... -
U.S. Small Molecule API Market Forecast to Reach USD 103.37 Billion by 2035, Driven by HPAPI and Domestic Manufacturing
Precedence Research USA Overview This article presents an overview of a market research report published by Precedence Research, which projects the U.S. small molecule API market to reach USD 103.37 billion by 2035. Key growth drivers in... -
Silexion Therapeutics Initiates GMP Manufacturing for KRAS-Driven Cancer siRNA Therapy SIL204, Secures Phase 2/3 Trial Approval
Manila Times (via GlobeNewswire) ケイマン諸島 Overview Silexion Therapeutics has commenced GMP clinical batch manufacturing for SIL204, its next-generation siRNA therapeutic targeting mutated KRAS oncogenes. Concurrently, the company rec... -
Viral Vector Manufacturing Market Projected to Reach USD 12.84 Billion by 2036: Driven by Gene Therapy Advances and CDMO Role
OpenPR Global Overview This article provides an overview of a market research report distributed by OpenPR. The report forecasts that the global viral vector manufacturing market will reach USD 12.84 billion by 2036, driven by the increa... -
EktaH Reveals Promising Early-Phase Data for Novel Obesity Drug NKS-3, Targeting Fat Loss with Muscle Retention
European Biotechnology Global Overview EktaH has released early clinical trial data for its novel obesity drug candidate, NKS-3, demonstrating promising results in both fat reduction and muscle preservation. Preclinical mouse data indica... -
Eli Lilly’s Oral Orforglipron Effective in Older Adults with Obesity, Receives FDA Approval as Non-Peptide GLP-1 Offering Dosing Flexibility
Medscape USA Overview Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron (Foundayo), demonstrated clinically significant weight loss and a favorable safety profile in obese adults aged 65 and older, similar to younger popul... -
Precision Peptide Company (BPC) Pioneers Advanced Peptide Manufacturing with Continuous Flow Synthesis and AI Integration to Meet GLP-1 Demand
Bitget アイルランド Overview Precision Peptide Company Inc. (BPC) is emerging as a critical CDMO partner for GLP-1 agonists, oncology vaccines, and targeted radiopharmaceuticals. Their proprietary "Flow-Peptide" continuous flow synthesis... -
Novo Nordisk’s CagriSema Achieves Over 22% Weight Loss in Phase 3 Trials: Synergistic Benefits of GLP-1 and Amylin Analog
Life Science Daily News Global Overview Novo Nordisk's CagriSema, a combination therapy featuring a GLP-1 receptor agonist and the amylin analog cagrilintide, demonstrated over 22% weight reduction in Phase 3 trials. Specifically, the RE... -
Divi’s Labs: The ‘TSMC of Pharma’ for Peptides? GLP-1 Demand Elevates Manufacturing to Strategic Imperative
Antifragile Thinking Global Overview The surging global demand for GLP-1 therapeutics has transformed peptide manufacturing into one of the most strategically critical areas within the CDMO sector. India's Divi's Labs stands out as a key...
